Comprehensive genomic profiling of lung cancer using a validated panel to explore therapeutic targets in East Asian patients-Reference-Cited by-同舟云学术

Comprehensive genomic profiling of lung cancer using a validated panel to explore therapeutic targets in East Asian patients

Published:2017-10-20 Issue:12 Volume:108 Page:2487-2494
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Liu Liping¹²,Liu Jilong³,Shao Di³⁴^ORCID,Deng Qiuhua¹²,Tang Hailing¹²,Liu Zu³,Chen Xuewei¹⁵,Guo Fengming³,Lin Yongping⁶,Mao Mao³,Kristiansen Karsten³⁴,Ye Mingzhi³⁴,He Jianxing¹⁵

Affiliation:

1. State Key Laboratory of Respiratory Diseases National Clinical Research Center for Respiratory Disease Guangzhou Institute of Respiratory Disease GuangzhouChina

2. The Translational Medicine Laboratory The First Affiliated Hospital of Guangzhou Medical University GuangzhouChina

3. BGI‐Shenzhen Shenzhen China

4. Laboratory of Genomics and Molecular Biomedicine Department of Biology University of Copenhagen Copenhagen Denmark

5. Department of Thoracic Surgery The First Affiliated Hospital of Guangzhou Medical University Guangzhou China

6. Department of Laboratory Medicine The First Affiliated Hospital of Guangzhou Medical University Guangzhou China

Funder

Science and Technology Planning Project of Guangzhou, People's Republic of China

Guangzhou Health and Medical Collaborative Innovative Major Special Projects

Natural Science Foundation for Distinguished Young Scholars of Guangdong Province

National Key R&D Program of China

Guangzhou Precision Medical Research Project

Guangdong Applied Technology Research and Development Project

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.13410

Reference41 articles.

1. Genomic Medicine Frontier in Human Solid Tumors: Prospects and Challenges

2. National Comprehensive Cancer Network.Clinical practice guidelines in oncology: non‐small cell lung cancer 2016. [Cited 5 Jul 2017.] Available from URL:http://www.nccn.org/professionals/physician_gls/f_guidelines.asp

3. Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology

4. The evolving genomic classification of lung cancer

5. Refining the treatment of NSCLC according to histological and molecular subtypes

Cited by 60 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Spatial whole exome sequencing reveals the genetic features of highly-aggressive components in lung adenocarcinoma;Neoplasia;2024-08

2. Landscape of Clinically Relevant Genomic Alterations in the Indian Non-small Cell Lung Cancer Patients;Clinical Lung Cancer;2024-07

3. Pitavastatin sensitizes the EGFR-TKI associated resistance in lung cancer by inhibiting YAP/AKT/BAD-BCL-2 pathway;Cancer Cell International;2024-06-28

4. Genomic landscape and tumor mutational features of resected preinvasive to invasive lung adenocarcinoma;Frontiers in Oncology;2024-05-13

5. Comparative Analysis of Mutation in the Buccal Epithelium and Blood in Patients with Lung Cancer and Healthy People;Russian Journal of Genetics;2024-05